Future Prospects in Breast Cancer Research - Cancer Stem Cells.
Breast cancer is one of the leading causes of cancer deaths among women. Although significant advances in the prevention, diagnosis and management are made, still every year half a million women die of breast cancer. Personalised treatment has the potential to increase treatment efficacy, and hence decrease mortality rates. Moreover, understanding cancer biology and translating this knowledge to the clinic, will improve the breast cancer therapy regime tremendously. Recently, it has been proposed that cancer stem cells (CSC) play an important role in tumour biology. CSC have the ability for self-renewal and are pivotal in setting the heterogeneous character of a tumour. Additionally, CSC possess several characteristics that make them resistant and more aggressive to the conventional chemo- and radiotherapy. Nowadays, breast cancer therapy is focused on killing the differentiated tumour cells, leaving the CSC unharmed, potentially causing recurrence of the disease and metastasis. Specific targeting of the CSC will improve the disease-free survival of breast cancer patients. In this article, two methods are described, aiming at specifically attacking the differentiated tumour cells ('Apoptosis chip') and the cancer stem cell. For this, microfluidics is used.
BIOS, Lab on a Chip Group, MESA+ Institute for Nanotechnology, University of Twente , Enschede, The Netherlands.
Floor
F
Wolbers
Department of Obstetrics and Gynaecology.
Henk R
HR
Franke
Department of Surgery, Medisch Spectrum Twente, Hospital Group , Enschede.
Joost M
JM
Klaase
Laboratory for Pathology East Netherlands , Enschede.
Mariël
M
Brinkhuis
BIOS, Lab on a Chip Group, MESA+ Institute for Nanotechnology, University of Twente , Enschede, The Netherlands.
Albert
A
van den Berg
BIOS, Lab on a Chip Group, MESA+ Institute for Nanotechnology, University of Twente , Enschede, The Netherlands.
István
I
Vermes
apoptosis; breast cancer; cancer stem cell; drug screening; mammospheres; microfluidics
Breast Cancer Res Treat. 2010 Apr;120(3):655-61
20204499
Menopause. 2010 Jul;17(4):801-10
20632465
Cancer Cell. 2007 Mar;11(3):259-73
17349583
Nat Med. 2011 Mar;17(3):313-9
21386835
Int J Cancer. 2010 Dec 15;127(12):2893-917
21351269
J Clin Invest. 2010 Jan;120(1):41-50
20051635
J Clin Oncol. 2008 Jun 10;26(17):2813-20
18539959
Proc Natl Acad Sci U S A. 2008 Apr 15;105(15):5774-9
18391223
Biomed Microdevices. 2008 Oct;10(5):727-37
18523888
Adv Clin Chem. 1994;31:177-246
7879672
Nature. 2008 Apr 3;452(7187):564-70
18385730
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21737-42
21098263
Clin Chem. 2008 Nov;54(11):1770-9
18801934
Integr Biol (Camb). 2012 May;4(5):461-70
22388577
Curr Opin Chem Biol. 2010 Oct;14(5):556-67
20832352
Ann Epidemiol. 2009 Jul;19(7):468-83
19523595
Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1146-51
17227861
Apoptosis. 2004 May;9(3):385-92
15258471
Menopause. 2011 Mar;18(3):319-22
21178642
Mol Oncol. 2010 Oct;4(5):404-19
20599450
Science. 2012 Aug 10;337(6095):730-5
22855427
Cancer Biol Ther. 2010 Nov 15;10(10):955-60
21057215
Nature. 2001 Nov 1;414(6859):105-11
11689955
Nature. 2012 Aug 23;488(7412):527-30
22854777
Lab Chip. 2011 Jan 21;11(2):231-7
20978708